Also trades as FMS.
FME.DE
Strong BuyFull HouseFresenius Medical Care AG · Healthcare · Germany · $12.0B
EUR 39.55 -0.3% · close 2 Oct · scored 6 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT FRESENIUS MEDICAL CARE AG
Read
Fresenius Medical Care AG is the world's leading provider of products and services for individuals with chronic kidney failure, offering life-sustaining dialysis treatments, dialysis machines, and related medical devices. The company's formidable competitive moat is built on its dominant global market share, extensive network of dialysis clinics, and continuous innovation in an essential healthcare sector. High capital intensity and regulatory complexities create significant barriers to entry, solidifying Fresenius Medical Care's leadership position.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.4B | 19.5B | 19.3B | 19.6B | 0.4% | 19.5B | 19.5B | 20.1B | 1.2% |
| EPS (EUR) | 2.30 | 1.70 | 1.83 | 3.36 | 13.5% | 3.34 | 3.19 | 3.34 | -0.3% |
| Shares | 293.4M | 293.4M | 293.4M | 279.3M | -4.8% | 266.1M | — | — | — |
| Debt | 13.2B | 12.1B | 11.0B | 10.8B | -6.5% | 11.0B | — | — | — |
| Equity | 14.0B | 13.6B | 14.6B | 13.3B | -1.6% | — | — | — | — |
| Op CF | 2.2B | 2.6B | 2.4B | 2.7B | 7.3% | 2.8B | — | — | — |
| Inv CF | -734.7M | -544.2M | -84.9M | -722.5M | — | — | — | — | — |
| Fin CF | -1.6B | -1.9B | -2.6B | -1.4B | — | — | — | — | — |
Calmer than 75% of stocks we rank over the past year (28% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FME.DE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FME.DE | Fresenius Medical Care AG(you) | $12.0B | 91 | Strong Buy |
| FRE.DE | Fresenius SE & Co. KGaA | $25.5B | 77 | Buy |
| RHK.DE | RHÖN-KLINIKUM Aktiengesellschaft | $1.1B | 83 | Strong Buy |
| MED.DE | MEDICLIN Aktiengesellschaft | $295M | 97 | Strong Buy |
| LIK.DE | LIMES Schlosskliniken AG | $180M | 88 | Strong Buy |
| 1846.HK | EuroEyes International Eye Clinic Limited | $97M | 75 | Buy |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.7B | 98 | Strong Buy |
| DMP.DE | Dermapharm Holding SE | $2.2B | 87 | Strong Buy |
| FIE.DE | Fielmann Group AG | $3.6B | 75 | Buy |
| AFX.DE | Carl Zeiss Meditec AG | $3.1B | 77 | Buy |
Peer medians: ROE 2.7% · P/E 20.9x · Gross margin 45.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.